Human Glucagon Receptor Antagonists Research Articles

QSAR study of active human glucagon receptor antagonists by SW-MLR and SW-SVM methods

A linear quantitative structure-activity relationship model is given for modelling and predicting of human glucagon receptor activities. A dataset containing 37 human glucagon receptors with their ...

Computational neural network analysis of the affinity of 2-pyridyl-3,5-diaryl pyrroles analogs for the human glucagon receptor using density functional theory

In our continuing efforts to provide a predictive quantitative structure activity relationship using different algorithms, radial basis function neural networks (RBFNN) have been successfully combined with principal component analysis (PCA) and trained to predict the biological activity (pIC50) of 2-pyridyl-3,5-diaryl pyrrole derivatives as human glucagon receptor antagonists. A set of quantum descriptors, including energy of HOMO, energy of LUMO, softness, hardness, etc. descriptors, were calculated using DFT-B3LYP method, with the basis set of 6-311G. An ANN with 1-15-1 architecture was generated using eight principal components. A principal component regression (PCR) model was also developed for comparison. It was found that a properly selected and trained RBFNN with a suitable training set could represent the dependence of the biological activity on the principal components that were calculated using quantum descriptors fairly well. For evaluation of the predictive ability of the developed PCA-based RBFNN model, an optimized network was applied to predict the pIC50s of compounds in the test set, which were not used in the modeling phase of the procedure. A squared correlation coefficient (R2) and root mean square error of 0.161 and 0.874 for the test set by the PCR model should be compared with the values of 0.999 and 0.0154 by the principal component based RBFNN model. These improvements are due to the fact that the pIC50s of 2-pyridyl-3,5-diaryl pyrrole derivatives show non-linear correlations with the principal component extracted from the quantum descriptors.

Discovery of N-Aryl-2-acylindole human glucagon receptor antagonists

A novel class of N-aryl-2-acylindole human glucagon receptor (hGCGR) antagonists is reported. These compounds demonstrate good pharmacokinetic profiles in multiple preclinical species. One compound from this series, indole 33, is orally active in a transgenic murine pharmacodynamic model. Furthermore, a 1mg/kg oral dose of indole 33 lowers ambient glucose levels in an ob/ob/hGCGR transgenic murine diabetes model. This compound was deemed suitable for preclinical safety studies and was found to be well tolerated in an 8-day experimental rodent tolerability study. The combination of preclinical efficacy and safety observed with compound 33 highlights the potential of this class as a treatment for type 2 diabetes.

Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists

In the course of the development of an aminobenzimidazole class of human glucagon receptor (hGCGR) antagonists, a novel class of cyclic guanidine hGCGR antagonists was discovered. Rapid N-dealkylation resulted in poor pharmacokinetic profiles for the benchmark compound in this series. A strategy aimed at blocking oxidative dealkylation led to a series of compounds with improved rodent pharmacokinetic profiles. One compound was orally efficacious in a murine glucagon challenge pharmacodynamic model and also significantly lowered glucose levels in a murine diabetes model.

ChemInform Abstract: Discovery of Novel, Potent, Selective, and Orally Active Human Glucagon Receptor Antagonists Containing a Pyrazole Core.

AbstractA novel class of 1,3,5‐substituted pyrazoles is discovered as potent human glucagon receptor antagonists.

Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core

A novel class of 1,3,5-pyrazoles has been discovered as potent human glucagon receptor antagonists. Notably, compound 26 is orally bioavailable in several preclinical species and shows selectivity towards cardiac ion channels, other family B receptors such hGIP and hGLP1, and a large panel of enzymes and additional receptors. When dosed orally, compound 26 is efficacious in suppressing glucagon induced plasma glucose excursion in rhesus monkey and transgenic murine pharmacodynamic models at 1 and 10mpk, respectively.

Human Glucagon Receptor Antagonists with Thiazole Cores. A Novel Series with Superior Pharmacokinetic Properties

The aim of the work presented here was to design and synthesize potent human glucagon receptor antagonists with improved pharmacokinetic (PK) properties for development of pharmaceuticals for the treatment of type 2 diabetes. We describe the preparation of compounds with cyclic cores (5-aminothiazoles), their binding affinities for the human glucagon and GIP receptors, as well as affinities for rat, mouse, pig, dog, and monkey glucagon receptors. Generally, the compounds had slightly less glucagon receptor affinity compared to compounds of the previous series, but this was compensated for by much improved PK profiles in both rats and dogs with high oral bioavailabilities and sustained high plasma exposures. The compounds generally showed species selectivity for glucagon receptor binding with poor affinities for the rat, mouse, rabbit, and pig receptors. However, dog and monkey glucagon receptor affinities seem to reflect the human situation. One compound of this series, 18, was tested intravenously in an anesthetized glucagon-challenged monkey model of hyperglucagonaemia and hyperglycaemia and was shown dose-dependently to decrease glycaemia. Further, high plasma exposures and a long plasma half-life (5.2 h) were obtained.

Novel Glucagon Receptor Antagonists with Improved Selectivity over the Glucose-Dependent Insulinotropic Polypeptide Receptor

Optimization of a new series of small molecule human glucagon receptor (hGluR) antagonists is described. In the process of optimizing glucagon receptor antagonists, we counter-screened against the closely related human gastric inhibitory polypeptide receptor (hGIPR), and through structure activity analysis, we obtained compounds with low nanomolar affinities toward the hGluR, which were selective against the hGIPR and the human glucagon-like peptide-1 receptor (hGLP-1R). In the best cases, we obtained a >50 fold selectivity for the hGluR over the hGIPR and a >1000 fold selectivity over the hGLP-1R. A potent and selective glucagon receptor antagonist was demonstrated to inhibit glucagon-induced glycogenolysis in primary rat hepatocytes as well as to lower glucagon-induced hyperglycemia in Sprague-Dawley rats. Furthermore, the compound was shown to lower blood glucose in the ob/ob mouse after oral dosing.

Discovery of Novel, Potent, and Orally Active Spiro‐Urea Human Glucagon Receptor Antagonists.

AbstractFor Abstract see ChemInform Abstract in Full Text.

Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists

A novel class of spiro-ureas has been discovered as potent human glucagon receptor antagonists in both binding and functional assays. Preliminary studies have revealed that compound 15 is an orally active human glucagon receptor antagonist in a transgenic murine pharmacodynamic model at 10 and 30 mpk. Compound 15 is orally bioavailable in several preclinical species and shows selectivity toward cardiac ion channels and other family B receptors, such as hGIP1 and hGLP.

Insight into the Bioactivity and Metabolism of Human Glucagon Receptor Antagonists from 3D‐QSAR Analyses

AbstractDescriptors, such as logP, the number of hydrogen bond donors, the number of hydrogen bond acceptors, highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) combined with fields of CoMFA and CoMSIA to construct models for hyperglycemia decrease activity and metabolism of human glucagon receptor antagonists. The results reveal that including logP, HOMO and LUMO energies is meaningful for QSAR/QSMR model. The models were validated by using a test set of structural diverse compounds that had not been included in the CoMFA and CoMSIA models. Support Vector Machines (SVM) have been used to select the suitable additional descriptors to construct 3D‐QSAR/QSMR models. A key factor to mention is that activity and metabolism models simultaneously. These in silico ADME models are helpful in making quantitative prediction of inhibitory activities and rates of metabolism before resorting in vitro and in vivo experimentation.

Biaryl amide glucagon receptor antagonists

Biaryl amides derived from a reported series of ureas 1 were evaluated and found to be potent human glucagon receptor antagonists. The benzofuran analogue 6i was administered in Sprague–Dawley rats and blocked the effects of an exogenous glucagon challenge.

Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide.

Highly potent human glucagon receptor (hGluR) antagonists have been prepared employing both medicinal chemistry and targeted libraries based on modification of the core (proximal) dimethoxyphenyl group, the benzyl ether linkage, as well as the (distal) benzylic aryl group of the lead 2, 3-cyano-4-hydroxybenzoic acid (3,5-dimethoxy-4-isopropylbenzyloxybenzylidene)hydrazide. Electron-rich proximal aryl moieties such as mono- and dimethoxy benzenes, naphthalenes, and indoles were found to be active. The SAR was found to be quite insensitive regarding the linkage to the distal aryl group, since long and short as well as polar and apolar linkers gave highly potent compounds. The presence of a distal aryl group was not crucial for obtaining high binding affinity to the hGluR. In many cases, however, the affinity could be further optimized with substituted distal aryl groups. Representative compounds have been tested for in vitro metabolism, and structure-metabolism relationships are described. These efforts lead to the discovery of 74, NNC 25-2504, 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide, with low in vitro metabolic turnover. 74 was a highly potent noncompetitive antagonist of the human glucagon receptor (IC(50) = 2.3 nM, K(B) = 760 pM) and of the isolated rat receptor (IC(50) = 430 pM, K(B) = 380 pM). Glucagon-stimulated glucose production from isolated primary rat hepatocytes was inhibited competitively by 74 (K(i) = 14 nM). This compound was orally available in dogs (F(po) = 15%) and was active in a glucagon-challenged rat model of hyperglucagonemia and hyperglycemia.

Human glucagon receptor antagonists based on alkylidene hydrazides

A series of alkylidene hydrazide derivatives containing an alkoxyaryl moiety was optimized. The resulting hydrazide-ethers were competitive antagonists at the human glucagon receptor. Pharmacokinetic experiments showed fast clearance of most of the compounds tested. A representative compound [4-hydroxy-3-cyanobenzoic acid (4-isopropylbenzyloxy-3,5-dimethoxymethylene)hydrazide] with an IC 50 value of 20 nM was shown to reduce blood glucose levels in fasted rats.

Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists.

The first non-peptide competitive human glucagon receptor antagonist, 2-(benzimidazol-2-ylthio)-1-(3,4-dihydroxyphenyl)-1-ethan one, NNC 92-1687 (2), is described. This antagonist has a binding affinity of 20 microM (IC50) and a functional Ki = 9.1 microM at the human glucagon receptor. A structure-activity relationship (SAR) was obtained on this compound, and the results show that only the benzimidazole part can be changed without complete loss of affinity. Analogues with tert-butyl or benzyloxy groups in the 5-position of the benzimidazole moiety were found to be equipotent or slightly more potent, all displaying binding affinities around 5-20 microM. Most of the changes to the catechol and the linker gave compounds without any affinity toward the human glucagon receptor. The 3-hydroxy group could, however, in the presence of a 4-hydroxy group be changed to a methoxy or a chloro group while retaining affinity.